Abstracts tagged "adverse events and cancer treatments"

Abstract Number: 2146 • 2019 ACR/ARP Annual Meeting
Complications of Immune Checkpoint Inhibitor Therapy in Patients with and Without Pre-existing Rheumatologic Disease
Emily Carroll¹, Amanda Leiter ², Danielle Brooks ¹, Jennifer Ben Shimol ³, Elliot Eisenberg ¹, Matthew Galsky ⁴, Emily Gallagher ⁵ and Margrit Wiesendanger ³, ¹Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ²Division of Endocrinology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ³Division of Rheumatology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, ⁴Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, ⁵Division of Endocrinology, Department of Medicine, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies in the treatment of many cancers, but their use has been linked with immune-related adverse events (irAEs).…
Abstract Number: 361 • 2018 ACR/ARHP Annual Meeting
Risk Factors of Immune-Related Adverse Events in Patients Treated with Anti-Programmed Cell Death 1 Antibody Pembrolizumab
In Young Kim¹, Yeonghee Eun¹, Hyungjin Kim¹, Joong Kyong Ahn², Eun-Jung Park³, Chan Hong Jeon⁴, Jinseok Kim⁵, Hoon-Suk Cha¹, Eun-Mi Koh¹ and Jaejoon Lee¹, ¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ²Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South), ³Department of Medicine, National Medical Center, Seoul, Korea, Republic of (South), ⁴Department of Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea, Republic of (South), ⁵Department of Medicine, Jeju National University Hospital, University of Jeju School of Medicine, Jeju, Korea, Republic of (South)
Background/Purpose: Immune checkpoint inhibitors have been established as a novel standard treatment for various types of malignancies. However, these new class of drugs have led…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.